

Charity Registration Number 1121784

Company Registration Number 06249601 (England and Wales)

---


**JUNE HANCOCK MESOTHELIOMA RESEARCH FUND**

**(COMPANY LIMITED BY GUARANTEE)**

**TRUSTEES' REPORT AND UNAUDITED**

**FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 30 JUNE 2024**



# JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

## CONTENTS

---

	Page
Legal and administrative information	1
Trustees' report	2 - 6
Statement of trustees' responsibilities	7
Independent Examiner's Report	8
Statement of financial activities	9
Balance sheet	10
Notes to the accounts	11-16

---

# JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

## LEGAL AND ADMINISTRATIVE INFORMATION

---

### Trustees

A Budgen  
K Hill  
K Stubbs  
R Hancock  
D Small

### Secretary

A Budgen

### Charity number

1121784

### Company number

06249601

### Principle address

Riverside East  
2 Millsands  
Sheffield  
S3 8DT

### Registered office

Riverside East  
2 Millsands  
Sheffield  
S3 8DT

### Accountants

Landin Wilcock & Co  
68 Queen Street  
Sheffield  
S1 1WR

### Bankers

CAF Bank  
25 Kings Hill Avenue  
Kings Hill  
West Malling  
Kent  
ME19 4TA

HSBC  
22, The Moor  
Sheffield  
S1 4PA

# **JUNE HANCOCK MESOTHELIOMA RESEARCH FUND**

## **TRUSTEES' REPORT**

### ***FOR THE YEAR ENDED 30 JUNE 2024***

---

The trustees, who are also the directors of the charity for the purposes of the Companies Act, submit their annual report and the unaudited financial statements of the June Hancock Mesothelioma Research Fund for the year ended 30 June 2024. Reference and administrative information set out on page 1 form part of this report. The trustees confirm that these financial statements comply with current statutory requirements, in that they have complied with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

#### **Structure, governance and management**

The June Hancock Mesothelioma Research Fund is a registered charity (charity number 1121784) and a company limited by guarantee (company number 06249601). The charity's only voting members are its charity trustees. It is currently managed by a committee of five who undertake all day to day tasks associated with running the charity and delivering its objectives. No paid staff are employed.

#### **Governing documents**

The charity was incorporated on 16th May 2007 and is governed by its Memorandum and Articles of Association. This report covers the accounting period for the year ended 30th June 2024.

#### **Recruitment of trustees**

The trustees meet regularly to discuss the charity's progress and formulate general policy. They are ultimately responsible for the day-to-day management of the charity, including the making, enforcing and altering of rules, and the authority for all expenditure. Trustees are elected and/or re-elected in accordance with the provisions set out in the organisation's constitution. The current operational management of the charity is conducted by the Trustees together with the help of several volunteers under the guidance of the trustees.

All decisions of a management nature are made by the board of trustees, the quorum is fifty percent.

The income and property of the charity shall be applied solely towards the promotion of its objects as set forth in the Memorandum of Association. No portion thereof shall be paid or transferred, directly or indirectly, by way of bonus or otherwise by way of profit, to members of the charity. No member of the board of trustees shall be appointed to any office of the charity paid by way of salary or fees. Neither shall they receive any remuneration or other benefit in money or kind from the charity.

The trustees, (who are also the directors for the purposes of company law), who served during the year were:

**A Budgen**

**K Hill**

**K Stubbs**

**R Hancock**

**D Small**

None of the trustees has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of a winding up.

New trustees are appointed by a resolution of the existing trustees, and there is no requirement for trustees to retire annually and seek re-appointment. New trustees undertake an induction and training process that includes an interview with the existing trustees at which stage they are given a presentation of the charity's objectives and activities. They will also be provided with a bible of documents that includes strategy information, financial accounts, trustee minutes, publicity materials, key project information and Charity Commission information about the responsibilities of Charity Trustees.

# **JUNE HANCOCK MESOTHELIOMA RESEARCH FUND**

## **TRUSTEES' REPORT (CONTINUED)**

### **FOR THE YEAR ENDED 30 JUNE 2024**

---

#### **Risk assessment**

The trustees have assessed the major risks to which the charity is exposed and are satisfied that systems are in place to mitigate exposure to these risks. The major risk to the charity is considered to be its reliance on donations and fund raising from the general public. A significant reduction in income would limit the development of the charity and the achievement of its objectives.

#### **Objectives and activities**

The objectives of the charity as described in its Memorandum are:

- Promoting research into the prevention, treatment, alleviation and cure of mesothelioma and other asbestos related conditions;
- Disseminating information about the said conditions (including but not limited to, the results of research funded by the JHMRF) for the benefit of the public provided that the objectives shall always be wholly and exclusively charitable.

The main policies undertaken through the financial year in furtherance of these objectives were:

- Accepting donations from those wishing to raise money specifically for research into mesothelioma. People who have encountered the disease in themselves or loved ones can take comfort from the knowledge that the money raised will fund research to help sufferers of the disease now and in the future.
- Providing high quality, easy to understand and up to date information on mesothelioma in publications and on our website. This includes information about the disease itself, treatments, clinical trials, novel therapies, where to go for more help, and also details of regional asbestos support groups.
- Supporting events like Action Mesothelioma Day to provide information to patients and carers, promote a better understanding of mesothelioma and raise awareness of the health implications of asbestos and asbestos products.
- Inviting applications for high quality mesothelioma research projects in the UK. All applications are independently reviewed and assessed by a panel of experts.

#### **Public benefit**

We remain confident that we demonstrate properly the public benefit expected by the Charity Commission in the way that our objectives state above. The above objectives and activities are clearly of value to mesothelioma patients and their carers, family and friends.

The trustees confirm that they have complied with the requirements of Section 4 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

#### **Use of volunteers**

There are no volunteers used in the daily duties of the charity, however, there are a number of academics and clinicians who volunteer to assist with the peer review process for new grant and fellowship applications, and interim and final reports submitted by existing grant holders.

# JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

## TRUSTEES' REPORT (CONTINUED)

**FOR THE YEAR ENDED 30 JUNE 2024**

---

### **Grant award policy**

The JHMRF runs a competitive award process when sufficient funds are available. Applications are invited in open, structured calls for high quality mesothelioma research projects. Health care professionals, post-doctoral scientists and other suitably qualified applicants are invited to apply for awards. Work must be carried out at a research institution in the UK. Research projects in basic science, translational research or applied health are considered but the primary focus must be mesothelioma.

The JHMRF funds major projects (up to £300,000), pump-priming grants (up to £25,000) and doctoral fellowships. A number of travel grants to attend scientific conferences or training courses are also available up to a maximum of £500. All applications received by the deadline are peer-reviewed by at least three independent expert referees, in accordance with AMRC guidelines. Our network of contacts provides a source of volunteer peer reviewers with specific medical and scientific expertise in a wide-range of areas. Applications and reviews are then scrutinised and prioritised by the JHMRF Scientific Advisory Group (SAG). The SAG comprises academics, research scientists and clinicians. It is currently chaired by a JHMRF trustee with research experience.

Research proposals are assessed against the following criteria:

- Quality of the research
- Importance of the research question(s)
- Relevance of the work to JHMRF research strategy
- Scientific potential of the research
- Originality of the research
- Ethicality and research governance of the research
- Sustainability of the research
- Management of the overall project

Additionally, fellowship applications are assessed for quality and suitability of the candidate, the host institution and the supervisor.

The review process generates a shortlist of prioritised applications, which is taken, to the JHMRF Board of Trustees. The Board makes the final decision on funding after consideration of the SAG's recommendations.

Funding calls are advertised on the websites of organisations such as RD Info, The British Lung Foundation and Mesothelioma UK and circulated to the mesothelioma research community via the distribution lists of special interest groups in the British Thoracic Oncology Group and the British Mesothelioma Interest Group.

### **Achievements and performance**

Fund raising activities have not fully recovered post-pandemic and this year the JHMRF has focused on consolidating funds in preparation for another funding round to open in 2025. While sponsored events and direct donations remain relatively low, the charity has been fortunate to receive a legacy and donations from our partner organisations raised at Action Mesothelioma Day (AMD) and other fund raising events held during the year. Due to increasing numbers of AMD events taking place in various locations across the country, the JHMRF trustees decided to continue the policy of raising awareness of the Fund by attending meetings organised by other groups. Trustees presented at AMD 2023 events run by patient support groups in Sheffield, Southampton and Manchester.

### **Principal Sources of Funding**

JHMRF's principal source of funding is generous donations, mainly from people affected by the disease. It has not engaged in any fundraising activities in the current year to 30 June 2024.

# **JUNE HANCOCK MESOTHELIOMA RESEARCH FUND**

## **TRUSTEES' REPORT (CONTINUED)**

### **FOR THE YEAR ENDED 30 JUNE 2024**

---

#### **Achievements and performance continued**

The JHMRF retains its commitment to building research capacity in mesothelioma by offering travel grants to support attendance at relevant training meetings and conferences. In 2024 the JHMRF awarded travel grants to three doctoral students from the Universities of Bradford, Liverpool and Sheffield Hallam to enable them to attend the 16th International Mesothelioma Interest Group (IMiG) 2023 conference held in the Lille Grand Palais, Lille, France. International conferences provide early career researchers with the opportunity to present their own work and network with other researchers to learn about new developments in mesothelioma research.

Their presentations included:

1. The role of Exportin-1 (XPO1) within cisplatin resistant Malignant Pleural Mesothelioma and specifically the use of Selinexor (KPT-330) a selective inhibitor of nuclear export which is currently used to treat haematological cancers;

2. A breathomics-based approach to improve malignant mesothelioma diagnosis;

3. Loss of BAP1 influences mesothelioma cellular motility suggesting new therapeutic approaches.

Throughout the year, the JHMRF has continued to work with external partners in the UK and Europe, including the European Lung Foundation, Asbestos Victim Support Groups and Mesothelioma Patient Support Groups. The JHMRF values these relationships to build a collaborative approach to mesothelioma research and drive improvements in treatment and care for patients.

#### **Financial review**

The Fund has continued to receive some extremely generous donations throughout the year. Donations come mainly from people affected by the disease.

The level and number of awards that will be offered in the future will necessarily be determined by the availability and sustainability of funding. Funds will be set aside to support annual applications for pilot and feasibility studies, and for travel and educational awards. The next call for a major project award will be announced in due course.

#### **Reserves policy**

The current level of reserves stands at £278,667. It is the policy of the charity to maintain unrestricted funds, which are the free reserves of the charity, the minimum level of reserves is £10,000. This provides sufficient funds to cover management, administration and support costs. Funds above this level will be available for the charity to support other projects in the future.

#### **Financial instruments**

##### **Objectives and policies**

The Charity's activities expose it to a number of financial risks including credit risk and liquidity risk. The use of financial derivatives is governed by the charity's policies approved by the board of trustees, which provide written principles on the use of financial derivatives to manage these risks. The Charity does not use derivative financial instruments for speculative purposes.

# JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

## TRUSTEES' REPORT (CONTINUED)

**FOR THE YEAR ENDED 30 JUNE 2024**

---

### Financial instruments - continued

#### Credit Risk

The Charity's principal financial assets are bank balances and cash, trade and other receivables, and investments.

The credit risk on liquid funds and derivative financial instruments is limited because the counterparties are banks with high credit-ratings assigned by international credit-rating agencies.

The Charity has no significant credit risk.

#### Liquidity risk

In order to maintain liquidity to ensure that sufficient funds are available for ongoing operations and future developments, the Charity uses a mixture of long-term and short-term debt finance.

Further details regarding liquidity risk can be found in the statement of accounting policies in the financial statements.


#### Plans for the future

The charity will continue to pursue its main aim, which is to promote high quality research into mesothelioma in the UK. The JHMRF will work closely with the new Mesothelioma Research Network and other research partners to build collaborations and develop ideas that have potential to lead to real advances in research and care for mesothelioma. We will adopt a flexible approach to funding using small grants and training awards to support innovative areas of research and major project awards to progress ideas further.

The patient will remain at the heart of the JHMRF research strategy; mesothelioma is a disease with extremely poor outcomes and limited treatment options. Improving care for people with mesothelioma and increasing the range of therapeutic options available to them is a priority area for the fund. We aim to achieve this by building a strong and well-balanced portfolio of research, the outputs from which will be of real benefit to patients.

Mesothelioma is classed as an industrial disease and is caused by asbestos exposure. The JHMRF will work in partnership with other organisations like the HSE and the International Ban Asbestos Secretariat to raise awareness of asbestos in order to reduce the risk of people contracting mesothelioma in the future. The JHMRF will continue to support the call for a worldwide ban on the mining and manufacture of asbestos products, and recognises the need to seek more sustainable methods of providing employment and shelter for vulnerable populations in developing countries.

On behalf of the board of trustees



Adrian Budgen  
Trustee  
Dated: 22 November 2024



Dan Small  
Trustee  
Dated: 22 November 2024



# JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

## STATEMENT OF TRUSTEES RESPONSIBILITIES

**FOR THE YEAR ENDED 30 JUNE 2024**

---

The trustees (who are also the directors of June Hancock Mesothelioma Research Fund for the purpose of company law) are responsible for preparing the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.


Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of its incoming resources and application of resource, including its income and expenditure, for the period.

In preparing these accounts, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare accounts on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the accounts comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the trustees of the Charity on 22 November 2024 and signed on its behalf by:



Adrian Budgen  
Trustee



Dan Small  
Trustee

# JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

## INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

**FOR THE YEAR ENDED 30 JUNE 2024**

---

I report on the accounts of the Charity for the year ended 30 June 2024 which are set out on pages 9 to 16.

Your attention is to be drawn to the fact that the Charity has prepared the Financial Statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has since been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2019.

### **Respective responsibilities of trustees and examiner**

The trustees (who are also the directors of the company for the purposes of company law) are responsible for the preparation of the accounts. The trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.

Having satisfied myself that the charity is not subject to audit under company law and is eligible for independent examination, it is my responsibility to:

- examine the accounts under section 145 of the 2011 Act;
- to follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and
- to state whether particular matters have come to my attention.

### **Basis of independent examiner's report**

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the Charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a 'true and fair view' and the report is limited to those matters set out in the statement

### **Independent examiner's statement**

In connection with my examination, no matter has come to my attention:

- (1) which gives me a reasonable cause to believe that in any material respect the requirements:
  - to keep accounting records in accordance with section 386 of the Companies Act 2006; and
  - to prepare accounts which accord with accounting records, comply with the accounting requirements of section 396 of the Companies Act 2006 and with the methods and principles of the statement of Recommended Practice: Accounting and Reporting by Charities have not been met; or
- (2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



Tom Henshaw ACA  
Landin Wilcock & Co  
Chartered Accountants & Registered Auditors  
68 Queen Street  
Sheffield  
S1 1WR

Dated: 18/12/24

# JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

## UNAUDITED STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 30 JUNE 2024

		Unrestricted funds	2024 Total	2023 Total
	Notes	£	£	£
<b><u>Income and Endowments from:</u></b>				
Income from Investments	2	13,649	13,649	6,146
Income from donations and legacies	3	35,450	35,450	40,274
Total income and endowments		49,099	49,099	46,420
<b><u>Expenditure on:</u></b>				
Charitable activity	4	1,908	1,908	5,496
Research Grants & Costs	6	1,259	1,259	597,580
Net gains on investments	11	(5,028)	(5,028)	1,052
Total resources expended		(1,861)	(1,861)	604,128
Net income/(expenditure)		50,960	50,960	(557,708)
Transfers between funds	10	-	-	-
Net movement in funds		50,960	50,960	(557,708)
Total funds brought forward		227,707	227,707	785,415
Total funds carried forward	13	278,667	278,667	227,707

The results for the year derive from continuing activities and there were no income, resources expended or transfers with any Designated or Restricted Funds during the current or preceding financial period.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

# JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

## UNAUDITED BALANCE SHEET

AS AT 30 JUNE 2024

		2024	As restated 2023
	Notes	£	£
<b>Current assets</b>			
Investments	11	183,164	173,814
Other debtors		1,105	882
Cash at bank and in hand		345,434	569,730
		<u>529,703</u>	<u>744,426</u>
<b>Liabilities</b>			
Creditors: amounts falling due within one year	12	1,260	1,032
Research Grants	6	178,189	215,911
		<u>(179,449)</u>	<u>(216,943)</u>
<b>Total assets less current liabilities</b>		<b>350,254</b>	<b>527,483</b>
Creditors due after more than one year: Research Grants	6	(71,587)	(299,776)
<b>Net Assets</b>		<u><b>278,667</b></u>	<u><b>227,707</b></u>
<b>Income funds</b>			
Unrestricted funds		278,667	227,707
<b>Accumulated funds</b>	13	<u><b>278,667</b></u>	<u><b>227,707</b></u>


The company is entitled to exemption from audit under Section 477 Companies Act 2006 for the year ended 30 June 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibility for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The accounts were approved by the board on 22 November 2024 and were signed by:



Adrian Budgen  
Trustee



Dan Small  
Trustee

# JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

## NOTES TO THE ACCOUNTS

### FOR THE YEAR ENDED 30 JUNE 2024

---

#### 1 Accounting policies

##### 1.1 Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

##### 1.2 Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Companies Act 2006 and the Charities Act 2011.

##### 1.3 Basis of preparation

June Hancock Mesothelioma Research Fund meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The presentation and functional currency is considered to be pounds sterling because this is the currency in the primary economic environment in which the Charity operates.

The prior year comparatives have been restated to reflect the following adjustment:

Fixed term cash deposits which mature over 6 months after the year end have been reclassified within current asset investments.

##### 1.4 Going concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

##### 1.5 Summary of disclosure exemptions

The Charity has opted to adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

##### 1.6 Fund accounting policy

Restricted funds are subject to specific conditions by donors as to how they may be used.

Unrestricted funds comprise funds that have been donated or generated through charitable activities which are not subject to any such usage conditions.

Designated funds are those either set aside by the trustees for specific purposes, or funds which are treated as such in order to follow accounting treatment guidelines as detailed within the Charities SORP (FRS 102) and the 2011 Charities Act.

Further details of each fund are disclosed in note 13.

##### 1.7 Incoming and endowments

Donations, legacies and other forms of voluntary income are recognised as incoming resources when there is entitlement, certainty of receipt, except insofar as they are incapable of financial measurement.

##### *Investment income*

Investment income is recognised on a receivable basis.

# JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

## NOTES TO THE ACCOUNTS (CONTINUED)

### FOR THE YEAR ENDED 30 JUNE 2024

---

#### 1.8 Resources expended

Resources expended are included in the Statement of Financial Activities on an accruals basis, inclusive of any VAT which cannot be recovered.

Expenditure which is directly attributable to charitable activities has been included in this cost category.

Governance costs are those incurred in the management and operation of the charity's projects and charitable activities, together with any compliance costs.

#### 1.9 Taxation

The Charity is considered to pass the test set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

#### 1.10 Cash and Cash Equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

#### 1.11 Financial Instruments

Classification:

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Charity after deducting all of its liabilities.

Recognition and measurement:

All financial assets and liabilities are initially measured at fair value, except for those financial assets classified as at fair value through income or expenditure, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangements constitutes a financing transaction.

If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the Charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when

- a) the contractual rights to the cash flows from the financial asset expire or are settled,
- b) the Charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or
- c) the Charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

# JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

## NOTES TO THE ACCOUNTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2024

### 2 Investment income

	2024	2023
	£	£
UK bank interest receivable	13,649	6,146

### 3 Incoming from donations and legacies

	2024	2023
	£	£
Donations receivable	35,450	40,274

### 4 Charitable activity costs

	2024	2023
	£	£
Fundraising and event expenditure	-	3,788
Governance costs	1,908	1,708
	1,908	5,496

### 5 Governance costs

	2024	2023
	£	£
Accountancy & Professional fees	1,437	1,121
Bank charges	351	480
Miscellaneous expenses	120	107
	1,908	1,708

# JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

## NOTES TO THE ACCOUNTS (CONTINUED)

**FOR THE YEAR ENDED 30 JUNE 2024**

---

### 6 Research Grants

	2024	2023
	£	£
Awarded in year:		
Projects and research fellowships	1,259	597,580
Charge in SOFA	1,259	597,580
Paid in the year	(267,170)	(97,189)
Movement	(265,911)	500,391
Balance at start of year	515,687	15,296
Balance at end of year	249,776	515,687
Due within one year	178,189	215,911
Due after more than one year	71,587	299,776
Balance at end of year	249,776	515,687

Grants awarded during the year:

JHMRF awarded travel grants to three doctoral students from the Universities of Bradford, Liverpool and Sheffield Hallam to enable them to attend the 16th International Mesothelioma Interest Group (IMiG) 2023 conference held in the Lille Grand Palais, Lille, France.

### 7 Trustees

No acting trustees (or any persons connected with them) received any remuneration during the year. No trustee travel expenses were reimbursed to Trustees during the year. (2023: £Nil).

### 8 Employees

Other than the trustees, the company had no employees.

### 9 Taxation

The Charity is a registered charity and is therefore exempt from taxation.

### 10 Transfers

There was no income or resources expended by way of any Designated or Restricted Funds, hence there were no transfers between funds during the period.



# JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

## NOTES TO THE ACCOUNTS (CONTINUED)

### FOR THE YEAR ENDED 30 JUNE 2024

#### 11 Investments

	2024 £	As restated 2023 £
<b>Quoted Investments &amp; Long Term Deposits</b>		
Balance at start of year	173,814	174,321
Additions in the year	4,321	545
Movement in valuation of investment	5,029	(1,052)
Balance at end of year	<u>183,164</u>	<u>173,814</u>

Investments includes an investment bond and two twelve month deposit accounts. At 30 June 2024 the market value of the bond was £64,240 and the amounts held on deposit total £118,924.

#### 12 Creditors: amounts falling due within one year

	2024 £	2023 £
Accruals	<u>1,260</u>	<u>1,032</u>

#### 13 Analysis of net assets between funds

	Unrestricted funds £	2024 Total £	2023 Total £
Fund balances at 30 June 2023 are represented by:			
Tangible fixed assets	-	-	-
Current assets	529,703	529,703	744,426
Creditors: amounts falling due within one year	(179,449)	(179,449)	(216,943)
Creditors: amounts falling due after more than one year	(71,587)	(71,587)	(299,776)
	<u>278,667</u>	<u>278,667</u>	<u>227,707</u>

#### 14 Contingent liabilities

There were no contingent liabilities as at 30 June 2024.

# **JUNE HANCOCK MESOTHELIOMA RESEARCH FUND**

## **NOTES TO THE ACCOUNTS (CONTINUED)**

***FOR THE YEAR ENDED 30 JUNE 2024***

---

**15 Capital commitments**

There were no capital commitments as at 30 June 2024.

**16 Post balance sheet events**

There are no events after the balance sheet date which the trustees feel should be brought to the attention of the members.

**17 Related Party Transactions**

There have been no related party transactions in the reporting period that require disclosure.